177 related articles for article (PubMed ID: 33356019)
1. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
Shaik N; LaBadie RR; Hee B; Chan G
Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
Shaik MN; Hee B; Wei H; LaBadie RR
Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
Shaik N; Hee B; Wei H; LaBadie RR
Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
[TBL] [Abstract][Full Text] [Related]
5. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
Shaik N; Hee B; Liang Y; LaBadie RR
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
[TBL] [Abstract][Full Text] [Related]
6. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
[TBL] [Abstract][Full Text] [Related]
8. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
Fan B; Dai D; Cohen M; Xu H; Yin F; Nagaraja R; Mobilia M; Almon C; Basile FG; Yang H
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):99-109. PubMed ID: 32648303
[TBL] [Abstract][Full Text] [Related]
9. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
[TBL] [Abstract][Full Text] [Related]
11. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
12. A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
Csonka D; Hazell K; Waldron E; Lorenzo S; Duval V; Trandafir L; Kobalava ZD
J Clin Pharmacol; 2016 Mar; 56(3):316-23. PubMed ID: 26183800
[TBL] [Abstract][Full Text] [Related]
13. Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study.
Song I; Chen G; Wu J; Ilic K
J Clin Pharmacol; 2023 Feb; 63(2):250-258. PubMed ID: 36089648
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
Chen X; Cui X; Pognan N; Quinlan M; Kapoor S; Rahmanzadeh G; Giovannini M; Marbury TC
Br J Clin Pharmacol; 2022 Jan; 88(1):91-102. PubMed ID: 34046915
[TBL] [Abstract][Full Text] [Related]
16. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
17. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
Park J; Kim CO; Oh ES; Lee JI; Kim JK; Ahn SH; Kim DY; Kim SU; Kim BK; Chung YE; Kim SM; Park MS
Clin Pharmacol Drug Dev; 2022 May; 11(5):576-584. PubMed ID: 35255191
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study.
Masters JC; Shaik N; Mendes da Costa L; Hee B; LaBadie RR
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):272-282. PubMed ID: 32790066
[TBL] [Abstract][Full Text] [Related]
19. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Miyatake D; Shibata T; Toyoshima J; Kaneko Y; Oda K; Nishimura T; Katashima M; Sakaki M; Inoue K; Ito T; Uchida N; Furihata K; Urae A
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):699-708. PubMed ID: 31833184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]